Traceability for cancer therapy

November 20, 2012, National Physical Laboratory
The secondary standard ionisation chambers at NPL that were used in the establishment of traceable 177Lu measurements at hospitals.

Scientists from the National Physical Laboratory (NPL) have worked to establish traceability for a molecular radiotherapy treatment for patients suffering from neuroendocrine tumours.

Neuroendocrine tumours are usually found in the or lungs and arise from hormone-producing cells. A new treatment involves the administration of a peptide, radiolabelled with the beta- and gamma-emitting radionuclide Lutetium-177 (177Lu), which irradiates the widespread without causing excessive damage to surrounding healthy tissue. The treatment can also be followed by , taking advantage of the gamma-emission of the radionuclide.

Following a series of clinical trials, this radiopharmaceutical is now beginning to be used routinely for molecular radionuclide therapy (MRT) throughout the UK and Europe.

A team of NPL scientists first established a link to the International Reference System by standardising 177Lu as part of an international comparison in 2011. Once that had been established, NPL invited UK and European hospitals that regularly use this radionuclide to participate in a blind exercise to measure the radioactivity in samples of 177Lu. From the results of this exercise, the hospitals could demonstrate traceability, ensuring regulatory compliance and . The results showed that the majority of participants have the capability to measure the 177Lu activity to within 2%, with only three participants showing variations higher than this.

The same team of scientists is now working on the next important step towards establishing traceability for 177Lu imaging, within the framework of a European Metrology Research Programme (EMRP) project called 'Metrology for Molecular Radiotherapy'.

Explore further: New therapy for childhood neuroblastoma proves feasible and safe

Related Stories

New therapy for childhood neuroblastoma proves feasible and safe

June 29, 2011
A new treatment option may soon be available for children with neuroblastoma according to research published in the July issue of The Journal of Nuclear Medicine. The study tested the principle that combined positron emission ...

Benefits of radionuclide therapy for neuroendocrine tumors

September 20, 2011
According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate) , is effective not only in ...

New radioisotope will improve cancer therapy

April 22, 2011
The high neutron flux at the Institut Laue-Langevin (ILL) has produced samples of 161Tb, an isotope of terbium with better properties for cancer therapy than existing radiopharmaceutical treatments. Researchers led by Paul ...

High-impact radiopeptide therapy halts neuroendocrine cancer

June 6, 2011
Research introduced at SNM's 58th Annual Meeting could be a sign of hope for patients with neuroendocrine cancer not responding well to standard therapies. Most radiotherapies use medical isotopes that emit beta radiation. ...

Radiotherapy doses to be more accurate

April 13, 2012
Cancer patients undergoing radiotherapy treatments in future will be safer thanks to a collaborative piece of research by NPL, the University of Montreal, and McGill University which will result in improved measurement consistency.

Recommended for you

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.